Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chemotherapy-Induced Neutropenia Treatment Market Grown from 2024 to 2025?
The market size for treatments of neutropenia induced by chemotherapy has seen robust growth in recent years. Its size is projected to increase from $0.59 billion in 2024 to $0.62 billion in 2025, registering a compound annual growth rate (CAGR) of 5.7%. The past growth period’s rise can be credited to the escalation in cancer diagnosis rates, increasing acceptance of chemotherapy, a rising elderly population, increased hospitalizations due to infections, and a growing portfolio of oncology drugs.
What Growth Rate Is Anticipated for the Chemotherapy-Induced Neutropenia Treatment Market in the Coming Years?
The market surrounding treatments for chemotherapy-induced neutropenia is forecasted to experience a significant upswing in growth over the forthcoming years. This market is projected to expand to $0.76 billion by 2029, with a compound annual growth rate (CAGR) of 5.3%. This anticipated growth can be connected to several factors, including an increased need for targeted neutropenia treatments, the rise in oncology research and development investment, a heightened emphasis on outpatient care, a wider use of biosimilars, and more awareness of infection prevention. The forecast period also points to several emerging trends, such as the advent of long-acting granulocyte colony-stimulating factor therapy (G-CSF) agents, a heightened reliance on combination therapies, a move towards home-based care solutions, an increase in biosimilar authorizations, and the inclusion of digital health monitoring tools.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
Who Are the Leading Companies in the Chemotherapy-Induced Neutropenia Treatment Market?
Major companies operating in the chemotherapy-induced neutropenia treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., GSK plc, Bristol-Myers Squibb Company, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Biogen Inc., Baxter Inteational, Fresenius Kabi, Eisai Co. Ltd., Dr. Reddy’s Laboratories Ltd., Exelixis Inc., Biocon Biologics Limited, Coherus BioSciences Inc., G1 Therapeutics, Enzychem Lifesciences Corporation
What Are the Key Drivers of the Chemotherapy-Induced Neutropenia Treatment Market?
The growth of the chemotherapy-induced neutropenia treatment market is likely to be driven by the escalating prevalence of cancer. Cancer is a set of diseases marked by uncontrolled multiplication and spread of abnormal cells in the body. The rising occurrence of cancer can be attributed to the aging population, as older people are at a higher risk of cancer due to the accumulation of genetic mutations and decreased immune function over time. By providing immune support and reducing infection risks, chemotherapy-induced neutropenia treatment plays a crucial role in cancer care, enabling patients to maintain chemotherapy treatments with fewer disruptions. It improves treatment results by mitigating complications, thus enhancing overall patient safety and quality of life. For example, data in July 2024 from the Australian Institute of Health and Welfare, a government body in Australia, reported a surge in cancer cases diagnosed in Australia to 160,570 in 2022, a jump of 3,789 cases from 156,781 in 2021. Therefore, the surge in cancer incidence is fueling the expansion of the chemotherapy-induced neutropenia treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24190&type=smp
What Are the Key Market Segments in the Chemotherapy-Induced Neutropenia Treatment Industry?
The chemotherapy-induced neutropenia treatment market covered in this report is segmented –
1) By Type: Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy (G-CSF), Granulocyte Transfusion, Other Types
2) By Route of Administration: Subcutaneous, Intravenous
3) By Indication: Solid Tumors, Hematological Malignancies, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Specialty Clinics, Homecare Settings
Subsegments:
1) By Antibiotic Therapy: Broad-Spectrum Antibiotics, Narrow-Spectrum Antibiotics, Prophylactic Antibiotics
2) By Granulocyte Colony-Stimulating Factor Therapy (G-CSF): Filgrastim, Pegfilgrastim, Lenograstim
3) By Granulocyte Transfusion: Allogeneic Granulocyte Transfusion, Autologous Granulocyte Transfusion
4) By Other Types: Antifungal Therapy, Stem Cell Therapy, Immunomodulatory Therapy
What Are the Latest Trends in the Chemotherapy-Induced Neutropenia Treatment Market?
Key players in the chemotherapy-induced neutropenia treatment market are concentrating on product innovation and securing approvals, like those for long-acting formulations, which boost patient convenience, decreases the frequency of doses, and strengthens treatment compliance. Long-acting formulations are drug preparations designed to slowly release active substances over an extended time frame, thus reducing the number of times the drug needs to be administered. In a specific case in December 2023, Coherus BioSciences Inc., an American biopharmaceutical firm, obtained the U.S. Food and Drug Administration (FDA) approval for Udenyca Onbody, an innovative, ready-to-use on-body injector. This apparatus, which includes a long-acting formulation, automatically provides pegfilgrastim just about 27 hours post-chemotherapy, dispensing with the requirement for an injection the following day. Udenyca Onbody augments the patient experience by guaranteeing timely preventive care for chemotherapy-induced neutropenia and reducing the number of clinic visits, thereby enhancing treatment adherence.
Access The Full Report Here:
What Are the Key Regional Markets in the Chemotherapy-Induced Neutropenia Treatment Industry?
North America was the largest region in the chemotherapy-induced neutropenia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chemotherapy-induced neutropenia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24190&type=smp
This Report Delivers Insight On:
1. How big is the chemotherapy-induced neutropenia treatment market, and how is it changing globally?
2. Who are the major companies in the chemotherapy-induced neutropenia treatment market, and how are they performing?
3. What are the key opportunities and risks in the chemotherapy-induced neutropenia treatment market right now?
4. Which products or customer segments are growing the most in the chemotherapy-induced neutropenia treatment market?
5. What factors are helping or slowing down the growth of the chemotherapy-induced neutropenia treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model